NCT00539136 is a Phase 1 clinical trial of GSK561679 tablet or solution in Healthy Subjects, sponsored by GlaxoSmithKline.

Who is sponsoring NCT00539136?

NCT00539136 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00539136?

Interventions in NCT00539136: GSK561679 tablet or solution.

What condition does NCT00539136 study?

NCT00539136 studies Healthy Subjects.

Is NCT00539136 still recruiting?

NCT00539136 is currently completed. Last updated 14 October 2010.

Last reviewed 2010-10-14 · How we verify

NCT00539136

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-label, Single-dose, Non-randomized, Balanced Design Three-way Cross-over Study to Examine the Variability in Absorption of GSK561679 Using Gamma Scintigraphy, PillCam™ SB Capsule and the Acoustic Vest in Healthy Males Volunteers

Completed Phase 1 Last updated 14 October 2010

What this trial tests

Phase 1 trial testing GSK561679 tablet or solution in Healthy Subjects in 12 participants. Completed in 1 March 2008.

Timeline

1 October 2007

Primary endpoint
1 March 2008

1 March 2008

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Primary purpose	diagnostic
Enrollment	12
Start date	1 October 2007
Primary completion	1 March 2008
Estimated completion	1 March 2008
Sites	1 location across United States

Drugs / interventions tested

GSK561679 tablet or solution — full drug profile →

Conditions studied

Healthy Subjects — all drugs for Healthy Subjects →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 55, male only, with Healthy Subjects. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Pharmacokinetic scope of GSK561679 after application in a solution and in a new tablet formula per treatment phase Complete gastric emptying of radioactive marker after application of GSK561679 Complete tablet breakdown per treatment phase

Sponsor's own description

This study will be conducted in healthy volunteers to investigate the absorption of GSK561679 using Gamma Scintigraphy, PillCam™ SB capsule and the acoustic vest.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Progress in corticotropin-releasing factor-1 antagonist development.
Zorrilla EP, Koob GF. · · 2010 · cited 131× · PMID 20206287 · DOI 10.1016/j.drudis.2010.02.011

Verify or expand the search:

Other recruiting trials for Healthy Subjects

Currently open trials in the same condition.

NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00539136 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 14 October 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00539136.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing